DOP2017000313A - Métodos de modulación de moléculas de vigilancia de adn citosólicas - Google Patents

Métodos de modulación de moléculas de vigilancia de adn citosólicas

Info

Publication number
DOP2017000313A
DOP2017000313A DO2017000313A DO2017000313A DOP2017000313A DO P2017000313 A DOP2017000313 A DO P2017000313A DO 2017000313 A DO2017000313 A DO 2017000313A DO 2017000313 A DO2017000313 A DO 2017000313A DO P2017000313 A DOP2017000313 A DO P2017000313A
Authority
DO
Dominican Republic
Prior art keywords
methods
modulation
molecules
cytosolic dna
dna surveillance
Prior art date
Application number
DO2017000313A
Other languages
English (en)
Inventor
Abraham Albert
Keil Daniel
Nickell Jason
Weiss Christian
Ilg Thomas
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of DOP2017000313A publication Critical patent/DOP2017000313A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Métodos para generar una respuesta inmunológica en un sujeto mediante la activación de moléculas y vías de señalización de inmunidad innata específicas. En particular, se usa una composición inmunomoduladora para estimular moléculas y vías de señalización de inmunidad innata
DO2017000313A 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas DOP2017000313A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
DOP2017000313A true DOP2017000313A (es) 2018-02-28

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000313A DOP2017000313A (es) 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas

Country Status (22)

Country Link
US (1) US20190233825A1 (es)
EP (1) EP3313376A2 (es)
JP (1) JP2018518511A (es)
KR (1) KR20180021874A (es)
CN (1) CN108472255A (es)
AR (1) AR105160A1 (es)
AU (1) AU2016282879A1 (es)
BR (1) BR112017028121A2 (es)
CA (1) CA2990526A1 (es)
CL (1) CL2017003373A1 (es)
CR (1) CR20180003A (es)
DO (1) DOP2017000313A (es)
HK (1) HK1256128A1 (es)
IL (1) IL256264A (es)
MX (1) MX2017017141A (es)
PE (1) PE20181208A1 (es)
PH (1) PH12017502413A1 (es)
RU (1) RU2018102915A (es)
SG (1) SG10201913395VA (es)
TW (1) TW201710509A (es)
UY (1) UY36756A (es)
WO (1) WO2016207314A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA3031778A1 (en) 2016-07-26 2018-02-01 Bayer Animal Health Gmbh Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2002024899A2 (en) * 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
WO2006017857A2 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
JP5530065B2 (ja) * 2004-08-13 2014-06-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
SI2992899T1 (sl) * 2009-05-14 2020-10-30 Bayer Intellectual Property Gmbh Povečan imunski odziv pri ptičjih vrstah
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
IL256264A (en) 2018-02-28
MX2017017141A (es) 2018-03-09
UY36756A (es) 2017-01-31
CL2017003373A1 (es) 2018-06-29
EP3313376A2 (en) 2018-05-02
SG10201913395VA (en) 2020-03-30
PH12017502413A1 (en) 2018-06-25
CR20180003A (es) 2018-03-20
BR112017028121A2 (pt) 2018-09-04
RU2018102915A3 (es) 2019-12-05
WO2016207314A2 (en) 2016-12-29
HK1256128A1 (zh) 2019-09-13
KR20180021874A (ko) 2018-03-05
AU2016282879A1 (en) 2018-01-18
JP2018518511A (ja) 2018-07-12
CN108472255A (zh) 2018-08-31
RU2018102915A (ru) 2019-07-29
US20190233825A1 (en) 2019-08-01
AR105160A1 (es) 2017-09-13
CA2990526A1 (en) 2016-12-29
PE20181208A1 (es) 2018-07-23
TW201710509A (zh) 2017-03-16
WO2016207314A3 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
DOP2017000313A (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201691374A1 (ru) Инсулин длительного действия и его применение
MX2016013950A (es) Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
BR112016023494A2 (pt) método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
DK3093022T3 (da) Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma
CR20160444A (es) Proteínas de fusión uti
DK3144383T3 (da) Mikroorganisme af Corynebacterium-slægten til fremstilling af L-lysin og fremgangsmåde til fremstilling af L-lysin under anvendelse af denne
ITUB20152180A1 (it) Metodo migliorato per conciare una pelle animale.
BR112017012087A2 (pt) métodos de identificação de genes codificantes e não codificantes coexpressados, e sistema
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi
EA201691203A1 (ru) Твёрдые формы тенофовира
AR110040A1 (es) Proteínas de unión biespecíficas